Menu

Assine Login/Cadastro

Índice Bovespa

US Dollar vs BRL

Cadastre-se para alertas em tempo real, use o simulador personalizado e observe os movimentos do mercado.

Cadastre-se

NVS Novartis AG

97,15

-0,59 (-0,6%)

Última atualização: 13:16:05

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/19/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert Kowalski

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2023 até Nov 2023

Click aqui para mais gráficos Novartis.

Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Nov 2022 até Nov 2023

Click aqui para mais gráficos Novartis.

Notícias Novartis AG

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Terça, 28 de Novembro de 2023 (5 horas atrás) • Edgar (US Regulatory)

Novartis Raises Mid-Term Sales Growth Targets
Terça, 28 de Novembro de 2023 (9 horas atrás) • Dow Jones News

Legend Biotech Subsidiary in License Agreement With Novartis
Segunda, 13 de Novembro de 2023 (2 semanas atrás) • Dow Jones News

Get Ready for Next Generation of Diabetes, Weight-Management Drugs
Quarta, 1 de Novembro de 2023 (4 semanas atrás) • InvestorsHub NewsWire

Novartis Skin Treatment Drug Cosentyx Gets US FDA Approval
Quarta, 1 de Novembro de 2023 (4 semanas atrás) • Dow Jones News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Segunda, 30 de Outubro de 2023 (4 semanas atrás) • Edgar (US Regulatory)

Novartis to Seek US Accelerated Approval of Atrasentan After Phase 3 Study Met Primary Goal
Segunda, 30 de Outubro de 2023 (4 semanas atrás) • Dow Jones News

Novartis Says FDA Deems Pluvicto Shortage Resolved, Supply Set to Increase Into 2024
Sexta, 27 de Outubro de 2023 (1 mês atrás) • Dow Jones News

Tuesday’s Wall Street Highlights: Coinbase, Intel, Redfin, Barclays, General Dynamics, GE, and more
Terça, 24 de Outubro de 2023 (1 mês atrás) • IH Market News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Terça, 24 de Outubro de 2023 (1 mês atrás) • Edgar (US Regulatory)

Novartis Raises Earnings Guidance Again After Key Drugs Boost Profit, Sales -- Update
Terça, 24 de Outubro de 2023 (1 mês atrás) • Dow Jones News

Novartis Raises Earnings Guidance After Key Drugs Boost Profit, Sales
Terça, 24 de Outubro de 2023 (1 mês atrás) • Dow Jones News

Mais Notícias de Novartis AG

Índice Bovespa

Grupo Casas Bahia ON

TRIUNFO PART ON

$Logo da Infracommerce Caxaas ON (IFCM3).$

Infracommerce Caxaas ON

CAMIL ALIMENTOS ON

Cotações da NYSE e AMEX têm defasagem de no mínimo 20 minutos.
Quaisquer outras cotações têm defasagem de no mínimo 15 minutos quando não especificado.
Em caso de dúvidas por favor entre em contato com o suporte: suporte@advfn.com.br ou (11) 4950 5808.

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

Support: (11) 4950 5808 | suporte@advfn.com.br

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea